Methods and materials for treating cancer

Patent metadata

Field	Value
Publication number	US-10556965-B2
Application number	US-201715417721-A
Country	US
Kind code	B2
Filing date	Jan 27, 2017
Priority date	Jan 28, 2016
Publication date	Feb 11, 2020
Grant date	Feb 11, 2020

Abstract

This document provides methods and materials related to treating cancer. For example, methods and materials for using particles (e.g., nanoparticles) containing (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell) and (b) one or more molecules having the ability to bind to an APC (e.g., a human macrophage) to treat cancer are provided.

First claim

What is claimed is:

1. A composition comprising particles, wherein said particles have a longest dimension of 1000 nm or less and comprise (a) an anti-cancer antigen antibody and (b) calreticulin, wherein incubation of cancer cells and antigen presenting cells in the presence of said composition results in increased phagocytosis of said cancer cells by said antigen presenting cells as compared to the level of phagocytosis of comparable cancer cells by comparable antigen presenting cells in the absence of said composition,
wherein said anti-cancer antigen antibody is conjugated to a surface of said particles,
wherein said anti-cancer antigen antibody is an anti-CD340 antibody, an anti-EGFR antibody, or an anti-PSMA antibody.

2. The composition of claim 1 , wherein said longest dimension is between 5 nm and 100 nm.

3. The composition of claim 1 , wherein said longest dimension is between 10 nm and 50 nm.

4. The composition of claim 1 , wherein said longest dimension is between 20 nm and 40 nm.

5. The composition of claim 1 , wherein said human calreticulin is a human calreticulin.

6. The composition of claim 1 , wherein said cancer cells are breast cancer cells, brain cancer cells, prostate cancer cells, lung cancer cells, or colorectal cancer cells.

7. The composition of claim 1 , wherein said cancer cells are human breast cancer cells, human brain cancer cells, human prostate cancer cells, human lung cancer cells, or human colorectal cancer cells.

8. The composition of claim 1 , wherein said antigen presenting cells are macrophages.

9. The composition of claim 1 , wherein said antigen presenting cells are human macrophages.

10. The composition of claim 1 , wherein said increased phagocytosis is at least a two-fold increase.

11. The composition of claim 1 , wherein said increased phagocytosis is at least a four-fold increase.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Kim Yon Son Betty
• Wharen Jr Robert E
• Yuan Hengfeng
• Jiang Wen

Classifications

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• A61K9/51

  Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K16/32 Primary

  against translation products of oncogenes · CPC title